Mabvax Therapeutics (MBVX) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 14, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'MBVX	'
Entity Registrant Name	'MABVAX THERAPEUTICS HOLDINGS, INC.	'
Entity Central Index Key	'0001109196	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	2,183,032

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Series A Redeemable Convertible Preferred Stock [Member]	Series B Redeemable Convertible Preferred Stock [Member]	Series B Telik Redeemable Convertible Preferred Stock [Member]	Series A-1 Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]
			MabVax [Member]	MabVax [Member]	MabVax [Member]
Current assets:	'	'	'	'	'	'	'
Cash and cash equivalents	$3,452,556	$354,254	'	'	'	'	'
Receivable	26,963	'	'	'	'	'	'
Prepaid expenses	415,751	44,408	'	'	'	'	'
Other current assets	25,360	'	'	'	'	'	'
Total current assets	3,920,630	398,662	'	'	'	'	'
Property and equipment, net	54,710	24,487	'	'	'	'	'
Goodwill	6,157,681	'	'	'	'	'	'
Other	'	14,285	'	'	'	'	'
Total assets	10,133,021	437,434	'	'	'	'	'
Current liabilities:	'	'	'	'	'	'	'
Accounts payable	666,585	66,977	'	'	'	'	'
Accrued compensation	390,773	169,123	'	'	'	'	'
Accrued clinical operations and site costs	426,492	773,523	'	'	'	'	'
Related party liabilities	'	240,000	'	'	'	'	'
Other accrued expenses	1,019,710	24,963	'	'	'	'	'
Warrant Liability	341,301	'	'	'	'	'	'
Total current liabilities	2,844,861	1,274,586	'	'	'	'	'
Commitments and contingencies	'	'	'	'	'	'	'
Redeemable Preferred stock:	'	'	'	'	'	'	'
Redeemable convertible preferred stock, value	1,787,614	12,525,182	5,787,906	6,737,276	1,787,614	'	'
Stockholders' equity (deficit):	'	'	'	'	'	'	'
Convertible preferred stock	'	'	'	'	'	6,891,572	1,190
Common stock	18,689	2,305	'	'	'	'	'
Additional paid-in capital	21,466,110	607,913	'	'	'	'	'
Accumulated deficit	-22,877,015	-13,972,552	'	'	'	'	'
Total stockholders' equity (deficit)	5,500,546	-13,362,334	'	'	'	'	'
Total liabilities, redeemable preferred stock and stockholders' equity (deficit)	$10,133,021	$437,434	'	'	'	'	'

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	150,000,000	'
Common stock, shares issued	1,868,914	230,503
Common stock, shares outstanding	1,868,914	230,503
Series A-1 Convertible Preferred Stock [Member]	'	'
Preferred stock, shares authorized	2,763,000	'
Convertible preferred stock, shares issued	2,762,841	'
Convertible preferred stock, shares outstanding	2,762,841	'
Convertible preferred stock, liquidation preference	$4,803,006	'
Series C Convertible Preferred Stock [Member]	'	'
Preferred stock, shares authorized	200,000	'
Convertible preferred stock, shares issued	118,970	'
Convertible preferred stock, shares outstanding	118,970	'
Convertible preferred stock, liquidation preference	0	'
MabVax [Member] | Series A Redeemable Convertible Preferred Stock [Member]	'	'
Redeemable convertible preferred stock, shares authorized	'	956,240
Redeemable convertible preferred stock, shares issued	'	956,240
Redeemable convertible preferred stock, shares outstanding	'	956,240
Redeemable convertible preferred stock, aggregate liquidation value	'	8,013,996
MabVax [Member] | Series B Redeemable Convertible Preferred Stock [Member]	'	'
Redeemable convertible preferred stock, shares authorized	'	2,000,000
Redeemable convertible preferred stock, shares issued	'	891,485
Redeemable convertible preferred stock, shares outstanding	'	891,485
Redeemable convertible preferred stock, aggregate liquidation value	'	6,509,866
MabVax [Member] | Series B Telik Redeemable Convertible Preferred Stock [Member]	'	'
Redeemable convertible preferred stock, shares authorized	1,250,000	'
Redeemable convertible preferred stock, shares issued	1,250,000	'
Redeemable convertible preferred stock, shares outstanding	1,250,000	'
Redeemable convertible preferred stock, aggregate liquidation value	$2,576,712	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Grants	$62,492	$22,381	$219,832	$253,519
Other	10,000	'	10,000	'
Total revenues	72,492	22,381	229,832	253,519
Operating costs and expenses:	'	'	'	'
Research and development	1,070,574	1,012,256	2,401,090	2,317,165
General and administrative	2,511,201	352,927	4,437,371	1,101,377
Total operating costs and expenses	3,581,775	1,365,183	6,838,461	3,418,542
Loss from operations	-3,509,283	-1,342,802	-6,608,629	-3,165,023
Interest and other income (expense)	-27	-515	-291	-1,305
Change in fair value of warrant liability	226,584	'	226,584	'
Net loss	-3,282,726	-1,343,317	-6,382,336	-3,166,328
Deemed dividend on Series A-1 preferred stock	'	'	-2,214,911	'
Accretion of preferred stock dividends	-213,452	'	-307,216	'
Net loss available to common stockholders	($3,496,178)	($1,343,317)	($8,904,463)	($3,166,328)
Basic and diluted net loss per share	($2.14)	($5.83)	($12.15)	($13.74)
Shares used to calculate basic and diluted net loss per share	1,631,932	230,503	732,962	230,503

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock, Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (USD $)

Total

Redeemable Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

January [Member]

January [Member]

February [Member]

February [Member]

February [Member]

June and July [Member]

June and July [Member]

June and July [Member]

June [Member]

June [Member]

July [Member]

July [Member]

July [Member]

July 8, 2014 [Member]

July 8, 2014 [Member]

July 8, 2014 [Member]

July 7, 2014 [Member]

July 8 to Sept 30, 2014 [Member]

May 12, 2014 [Member]

May 12, 2014 [Member]

September 3, 2014 [Member]

September 8, 2014 [Member]

September 8, 2014 [Member]

September 8, 2014 [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Accumulated Deficit [Member]

Accumulated Deficit [Member]

Accumulated Deficit [Member]

Accumulated Deficit [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series A Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]

MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]

MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]

MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]

MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]

MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]

MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]

MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]

MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

MabVax Series A Convertible Preferred Stock [Member]

MabVax Series A Convertible Preferred Stock [Member]

MabVax Series A Convertible Preferred Stock [Member]

MabVax Series A Convertible Preferred Stock [Member]

MabVax Series A Convertible Preferred Stock [Member]

MabVax Series A Convertible Preferred Stock [Member]

MabVax Series A Convertible Preferred Stock [Member]

MabVax Series A Convertible Preferred Stock [Member]

MabVax Series A Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

MabVax Series B Convertible Preferred Stock [Member]

Series A-1 Convertible Preferred Stock [Member]

Series A-1 Convertible Preferred Stock [Member]

Series A-1 Convertible Preferred Stock [Member]

Series A-1 Convertible Preferred Stock [Member]

Series A-1 Convertible Preferred Stock [Member]

Series A-1 Convertible Preferred Stock [Member]

Series A-1 Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

Redeemable Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

July [Member]

July [Member]

USD ($)

February [Member]

June and July [Member]

July [Member]

September 3, 2014 [Member]

September [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

USD ($)

February [Member]

June and July [Member]

July [Member]

September 3, 2014 [Member]

September 8, 2014 [Member]

September [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

USD ($)

February [Member]

July 8, 2014 [Member]

July 8 to Sept 30, 2014 [Member]

May 12, 2014 [Member]

Redeemable Convertible Preferred Stock [Member]

February [Member]

June and July [Member]

June [Member]

July 8, 2014 [Member]

July 8 to Sept 30, 2014 [Member]

September 3, 2014 [Member]

September [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

January [Member]

February [Member]

June and July [Member]

June [Member]

July 8, 2014 [Member]

July 8 to Sept 30, 2014 [Member]

September 3, 2014 [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

February [Member]

June and July [Member]

July 8, 2014 [Member]

July 7, 2014 [Member]

July 8 to Sept 30, 2014 [Member]

September 3, 2014 [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

February [Member]

June and July [Member]

July [Member]

July 8 to Sept 30, 2014 [Member]

May 12, 2014 [Member]

September 3, 2014 [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

February [Member]

June and July [Member]

June [Member]

July [Member]

July 8, 2014 [Member]

July 7, 2014 [Member]

May 12, 2014 [Member]

Series A Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

January [Member]

February [Member]

June and July [Member]

June [Member]

July [Member]

July 8, 2014 [Member]

July 7, 2014 [Member]

May 12, 2014 [Member]

Series B Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

February [Member]

June and July [Member]

July [Member]

July 8, 2014 [Member]

July 8 to Sept 30, 2014 [Member]

May 12, 2014 [Member]

USD ($)

Convertible Preferred Stock [Member]

February [Member]

June and July [Member]

July [Member]

September 3, 2014 [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

July [Member]

July [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

July [Member]

July [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

July [Member]

July [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

July [Member]

July [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

July [Member]

July [Member]

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

July [Member]

July [Member]

USD ($)

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

July [Member]

USD ($)

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

July [Member]

USD ($)

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

USD ($)

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Redeemable Convertible Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Convertible Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Stockholders' equity, Beginning balance at Dec. 31, 2013

($13,362,334)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,305

'

'

'

'

'

'

'

$607,913

'

'

'

'

'

'

'

'

($13,972,552)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Temporary equity, Beginning balance at Dec. 31, 2013

12,525,182

12,525,182

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,787,906

'

'

'

'

'

'

'

'

'

6,737,276

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' equity, Beginning balance, shares at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

230,503

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Temporary equity, Beginning balance, shares at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

956,240

'

'

'

'

'

'

'

'

'

891,485

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accretion of redemption, value

307,216

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-99,200

99,200

'

'

'

-76,712

76,712

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-99,200

-84,184

-76,712

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

99,200

'

'

'

'

'

'

'

'

'

'

76,712

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

84,184

'

'

'

'

'

'

'

Accretion of redemption, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjusted for Merger and Reverse Split, and change in par from $0.001 per share to $0.01 per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in connection with exercise of warrants on a cashless basis, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,760

'

'

'

'

'

'

'

'

-2,760

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrant, value

'

'

'

1,942

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,472,502

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,942

'

'

'

'

'

'

'

'

'

'

'

'

1,472,502

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in connection with exercise of warrants on a cashless basis, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

276,041

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

276,041

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrant, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

194,281

'

'

'

'

'

'

'

'

'

'

'

'

1,827,979

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of accounts payable into common stock, value

'

'

'

'

'

240,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

445

'

'

'

'

'

'

'

239,555

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of accounts payable into common stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44,466

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of preferred stock, value

'

'

'

'

'

'

2,973,655

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,973,655

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, value

'

'

'

'

'

'

'

'

2,892,615

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,263

'

'

'

'

'

'

'

2,889,352

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

326,264

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,697,702

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed dividend related to beneficial conversion feature of MabVax Series C-1 preferred

'

'

'

'

'

-2,214,911

2,214,911

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,214,911

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,214,911

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of Series A and Series B to equity, value

'

'

'

'

'

'

'

'

'

'

'

12,527,124

-12,527,124

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,787,906

'

'

'

'

'

'

'

'

'

'

-6,739,218

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,787,906

'

'

'

'

'

'

'

'

'

6,739,218

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of Series A and Series B to equity, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-956,240

'

'

'

'

'

'

'

'

'

'

-1,085,766

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

956,240

'

'

'

'

'

'

'

'

'

1,085,766

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of preferred stock to common stock, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,807,388

-6,807,388

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,657

3,017

'

'

'

'

'

'

'

5,785,249

6,736,201

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,807,388

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,787,906

'

'

'

'

'

'

'

'

'

-6,739,218

'

'

'

'

6,807,388

'

'

'

'

'

'

'

'

Conversion of preferred stock to common stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

265,749

301,746

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,525,681

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-956,240

'

'

'

'

'

'

'

'

'

-1,085,766

'

'

'

'

2,762,841

'

'

'

'

'

'

'

'

Acquisition of Telik, Inc. at exchange ratio of 2.223284 shares of Telik for every share of MabVax, including 572,858 common and 1,250,000 Telik Series B outstanding, value

'

'

'

'

'

'

'

'

'

'

'

'

'

4,705,726

1,710,902

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,729

'

'

'

'

'

'

'

4,699,997

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,710,902

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition of Telik, Inc. at exchange ratio of 2.223284 shares of Telik for every share of MabVax, including 572,858 common and 1,250,000 Telik Series B outstanding, shares

276,041

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

572,858

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exchange of common stock for Series C, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,487

'

'

'

'

'

'

'

297

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,190

'

'

'

'

1,190

Exchange of common stock for Series C, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

148,713

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

118,970

Elimination of fractional shares resulting from Reverse Split

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-293

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-293

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

510,599

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

510,599

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-6,382,336

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,382,336

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' equity, Ending balance at Sep. 30, 2014

5,500,546

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,689

'

'

'

'

'

'

'

21,466,110

'

'

'

'

'

'

'

'

-22,877,015

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Temporary equity, Ending balance at Sep. 30, 2014

$1,787,614

$1,787,614

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,787,614

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,891,572

'

'

'

'

'

'

'

$1,190

'

'

'

'

Stockholders' equity, Ending balance, shares at Sep. 30, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,868,914

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Temporary equity, Ending balance, shares at Sep. 30, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,762,841

'

'

'

'

'

'

'

118,970

'

'

'

'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock, Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) (USD $)	9 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
	Redeemable Convertible Preferred Stock [Member]	January [Member]	February [Member]	February [Member]	June and July [Member]	June and July [Member]	June and July [Member]	June and July [Member]	July [Member]
		MabVax Series B Redeemable Convertible Preferred Stock [Member]	Redeemable Convertible Preferred Stock [Member]	MabVax Series C-1 Redeemable Convertible Preferred Stock [Member]		Redeemable Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Common Stock [Member]	Series B Redeemable Convertible Preferred Stock [Member]
		Redeemable Convertible Preferred Stock [Member]		Redeemable Convertible Preferred Stock [Member]					Redeemable Convertible Preferred Stock [Member]
Par value per share	$0.00	'	'	'	'	'	'	'	'
Change in par value per share	$0.01	'	'	'	'	'	'	'	'
Exercise of warrant, per share	'	$0.01	'	'	'	'	'	'	'
Conversion of accounts payable	'	'	$240,000	'	'	'	'	'	'
Conversion to common stock shares	'	'	44,466	'	'	'	'	'	'
Price per share	'	'	'	$0.84	'	$9.32	$9.32	$9.32	'
Issuance costs	'	'	'	$126,345	$148,021	$148,021	$148,021	'	'
Common stock exchange ratio	'	'	'	'	'	'	'	'	2.223284
Common stock, shares issued	'	'	'	'	'	'	'	'	572,858
Common stock, shares outstanding	'	'	'	'	'	'	'	'	1,250,000

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating activities	'	'
Net loss	($6,382,336)	($3,166,328)
Adjustments to reconcile net loss to net cash used for operating activities:	'	'
Depreciation and amortization	8,521	27,524
Stock-based compensation	510,599	244,983
Change in fair value of warrants	-226,584	'
Increase (decrease) in operating assets and liabilities excluding effects of the Merger:	'	'
Grants receivable	'	-21,516
Other receivables	3,629	'
Prepaid expenses - clinical operations	'	237,679
Prepaid expenses and other	-200,070	-15,925
Accounts payable	599,608	306,615
Accrued clinical operations and site costs	-347,031	87,014
Accrued compensation	39,699	-12,555
Other accrued expenses	293,014	-12,988
Net cash used in operating activities	-5,700,951	-2,325,497
Investing activities	'	'
Purchases of property and equipment	-38,744	'
Proceeds from Acquisition of Telik, Inc.	1,497,283	'
Net cash provided by investing activities	1,458,539	'
Financing activities	'	'
Issuances of preferred stock, net of issuance costs	2,973,655	1,999,999
Proceeds from issuance of common stock, net of issuance costs	2,892,615	'
Net cash provided by financing activities	7,340,714	1,999,999
Net change in cash and cash equivalents	3,098,302	-325,498
Cash and cash equivalents at beginning of period	354,254	421,197
Cash and cash equivalents at end of period	3,452,556	95,699
Supplemental disclosures:	'	'
Deemed dividend on beneficial conversion feature for preferred stock	2,214,911	'
Goodwill on acquisition of Telik, Inc.	6,157,681	'
Accretion of redemption value for Series C-1 and B preferred stock	307,216	'
Issuance of common stock for accounts payable	240,000	'
Warrants to purchase common stock were exercised on a cashless basis to purchase 276,041 shares of common stock. See Note 7.	2,760	'
Series A and Series B Redeemable Convertible Preferred Stock into Common Stock [Member]	'	'
Supplemental disclosures:	'	'
Conversion of preferred stock to common stock, value	12,527,124	'
Conversion of Series C-1 and A-1 Preferred Stock into Common Stock [Member]	'	'
Supplemental disclosures:	'	'
Conversion of preferred stock to common stock, value	6,807,388	'
Series B Preferred Stock [Member]	'	'
Supplemental disclosures:	'	'
Change in fair value of warrant liability in connection with issuance of warrants with Series B preferred stock	226,584	'
MabVax Series B Warrants [Member]	'	'
Financing activities	'	'
Proceeds from exercise of warrants	1,942	'
MabVax Series C-1 Warrants [Member]	'	'
Financing activities	'	'
Proceeds from exercise of warrants	1,472,502	'
Series C Convertible Preferred Stock [Member]	'	'
Supplemental disclosures:	'	'
Exchange of common stock for Series C preferred stock	$1,190	'

Condensed_Consolidated_Stateme4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	9 Months Ended
	Sep. 30, 2014
Statement of Cash Flows [Abstract]	'
Warrants to purchase common stock were exercised on a cashless basis to purchase common stock, shares	276,041

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	1. Basis of Presentation
	MabVax Therapeutics Holdings, Inc. (f.k.a. Telik, Inc. and referred to herein as “MabVax Therapeutics Holdings” or the “Company”) (OTCQB: MBVX) was incorporated in the state of Delaware on October 20, 1988. On July 8, 2014, Tacoma Acquisition Corp., a Delaware corporation and wholly owned subsidiary of MabVax Therapeutics Holdings (“Tacoma Corp.”) merged with MabVax Therapeutics, Inc., a Delaware corporation (“MabVax Therapeutics”) pursuant to an Agreement and Plan of Merger, dated May 12, 2014, by and among MabVax Therapeutics Holdings, Tacoma Corp. and MabVax Therapeutics, as amended by that certain Amendment No. 1 to the Merger Agreement, dated June 30, 2014, by and among the parties thereto and by that certain Amendment No. 2 to the Merger Agreement, dated July 7, 2014, by and among the parties thereto (such agreement as amended, the “Merger Agreement”; such merger, the “Merger”). Unless the context otherwise requires, references to “we,” “our,” “us,” or the “Company” in this Quarterly Report mean MabVax Therapeutics Holdings on a condensed consolidated financial statement basis with our wholly-owned subsidiary following the Merger, MabVax Therapeutics, as applicable. On October 9, 2014 FINRA approved our stock symbol change request and the Company began trading under the symbol MBVX (OTCQB: MBVX) on October 10, 2014.
	The balance sheet data at December 31, 2013, has been derived from audited financial statements at that date. It does not include, however, all of the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. Par value and additional paid-in capital for December 31, 2013 has been restated to reflect the par value for shares post-merger and the September 8, 2014 8-for-1 Reverse Split (as defined below).
	We are a clinical stage biopharmaceutical company engaged in the discovery, development and commercialization of proprietary human monoclonal antibody products and vaccines for the treatment of a variety of cancers. We have discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Therapeutic vaccines under development were discovered at Memorial Sloan Kettering Cancer Center (“MSKCC”), and are exclusively licensed to MabVax Therapeutics. We operate in only one business segment.
	We are continuing to evaluate the technology and development programs that were under way at MabVax Therapeutics Holdings prior to the Merger and plan to continue developing MabVax Therapeutics’ pre-Merger pipeline. We currently expect that we will cease patent applications and patent prosecutions for the Telintra development program in place at MabVax Therapeutics Holdings prior to the Merger.
	We have incurred net losses since inception and expect to incur substantial losses for the foreseeable future as the Company continues research and development activities. To date, we have funded operations primarily through government grants, the sale of preferred stock, equity securities, non-equity payments from collaborators and interest income. The process of developing the Company’s products will require significant additional research and development, preclinical testing and clinical trials, as well as regulatory approval. We expect these activities, together with general and administrative expenses, to result in substantial operating losses for the foreseeable future. We will not receive revenue unless the Company or its collaborative partners complete clinical trials, obtain regulatory approval and successfully commercialize one or more products; or the Company licenses its technology after achieving one or more milestones of interest to a potential partner.
	The accompanying unaudited condensed consolidated financial statements were prepared using GAAP for interim financial information and the instructions to Regulation S-X. Accordingly, these financial statements do not include all information or notes required by GAAP for annual financial statements and should be read in conjunction with the Audited Financial Statements of MabVax Therapeutics for the period from May 5, 2006 (inception) through December 31, 2013, filed with our Definitive Proxy Statement on Form DEFM14A on June 3, 2014.
	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
	Recent Accounting Pronouncements
	The Company has historically reported as a development stage Company. In the period ended June 30, 2014, the Company elected to early adopt FASB Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements.” The adoption of this ASU allows the Company to remove the inception to date information and all references to development stage.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606). ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. Additionally, this update supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition-Construction-Type and Production-Type Contracts.” The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It is effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities may choose from two adoption methods, with certain practical expedients. We are currently reviewing this standard to assess the impact on the Company’s future financial statements and evaluating the available adoption methods.
	In June 2014, the FASB issued ASU No. 2014-12, “Compensation—Stock Compensation” (Topic 718): “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. ASU No. 2014-12 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. We are currently reviewing this standard to assess the impact on the Company’s future financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, (“ASU 2014-15”), “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern”. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. Certain disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of the updated standard on the financial statements and disclosures.

Reverse_Stock_Split_Name_Chang

Reverse Stock Split, Name Change and Increase in Authorized Shares	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Reverse Stock Split, Name Change and Increase in Authorized Shares	'
	2. Reverse Stock Split, Name Change and Increase in Authorized Shares
	On September 8, 2014, MabVax Therapeutics Holdings filed an amended and restated certificate of incorporation to increase the authorized number of shares of our common stock to a new total of 150,000,000 shares, increase the number of shares of our preferred stock to a new total of 15,000,000 shares, and change the name of the Company from “Telik, Inc.” to “MabVax Therapeutics Holdings, Inc.” The amendment and restatement of the certificate of incorporation effectuating the name change and above authorized share increases were approved by our stockholders at the special stockholder meeting on September 8, 2014 and by our Board of Directors at a meeting of the Board held on September 8, 2014.
	On September 8, 2014, following the filing of the amended and restated certificate disclosed above, MabVax Therapeutics Holdings filed a certificate of amendment to the amended and restated certificate of incorporation to effect an 8-for-1 reverse stock split on common stock (the “Reverse Split”), effective as of 4:01 p.m. Eastern Time (the “Effective Time”) on September 8, 2014 (the “Effective Date”). The Reverse Split was approved by our stockholders at the special stockholder meeting held on September 8, 2014 and by the Board of Directors at a meeting of the Board held on September 8, 2014.
	On the Effective Date, immediately and without further action by our stockholders, every 8 shares of our common stock, issued and outstanding immediately prior to the Effective Time were automatically converted into 1 share of our common stock. As a result of the Reverse Split and calculated as of the Record Date, the number of outstanding shares of our common stock was reduced from 13,932,937 to approximately 1,741,617, excluding outstanding and unexercised share options and warrants and subject to adjustment for fractional shares. No fractional shares were issued as a result of the Reverse Split and, in lieu of these fractional shares, any holder of less than 1 share of our common stock was entitled to receive cash for such holder’s fractional share equal to the product of such fraction multiplied by the average of the last reported bid and ask prices of our common stock at 4:00 p.m., Eastern time, end of regular trading hours on OTCQB marketplace, during the 10 consecutive trading days ending on the last trading day prior to the Effective Date. Further, any options, warrants and contractual rights outstanding as of the Effective Date that were subject to adjustment were adjusted in accordance with their terms. These adjustments included, without limitation, changes to the number of shares of our common stock that may be obtained upon exercise or conversion of these securities, and changes to the applicable exercise or purchase price of such securities.
	Shares of our common stock began to trade on the OTCQB marketplace on a post-split basis under the name MabVax Therapeutics Holdings, Inc. on September 10, 2014 under the new CUSIP number 55414P108. MabVax Therapeutics Holdings retained the same CUSIP number when its common stock begin trading on the OTCQB marketplace under the trading symbol MBVX on October 10, 2014.
	All prior periods in these financial statements have been adjusted to reflect the effects of the Merger and the Reverse Split, unless otherwise indicated.

Liquidity_and_Going_Concern

Liquidity and Going Concern	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Liquidity and Going Concern	'
	3. Liquidity and Going Concern
	The accompanying condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company had a net loss of $6,382,336, net cash used in operations of $5,700,951 and net cash provided by investing activities of $1,458,539, for the nine months ended September 30, 2014. As of September 30, 2014, the Company had $3,452,556 in cash and cash equivalents and an accumulated deficit of $22,877,015.
	From February 13, 2014 through July 7, 2014, MabVax Therapeutics Holdings completed a series of financing transactions totaling approximately $7.3 million net of approximately $300,000 in issuance costs, through the sale of MabVax Therapeutics Holdings preferred stock, MabVax Therapeutics Holdings common stock and exercise of MabVax Therapeutics Holdings warrants.
	The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) continues to identify and advance a number of potential drug candidates into clinical and preclinical development activities, (ii) initiates manufacturing of its lead antibody candidate 5B1 and continues to fund its operations, and (iii) expands its corporate infrastructure, including the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations beyond June 2015, unless the Company is able to raise additional capital. These conditions give rise to substantial doubt as to the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company plans to continue to fund its losses from operations and capital funding needs through equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.
	If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.

Cash_and_cash_equivalents

Cash and cash equivalents	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and cash equivalents	'
	4. Cash and cash equivalents
	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed Federally insured limits. The Company has not experienced any losses on such accounts.

Fair_value_of_financial_instru

Fair value of financial instruments	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Fair value of financial instruments	'
	5. Fair value of financial instruments
	The Company’s financial instruments consist of cash and cash equivalents, other receivable, prepaid expenses and other current assets, accounts payable, warrant liability, and related party payables, all of which are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.

Merger_with_MabVax_Therapeutic

Merger with MabVax Therapeutics, Inc.	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Merger with MabVax Therapeutics, Inc.	'
	6. Merger with MabVax Therapeutics, Inc.
	On May 12, 2014, the Company entered into the Merger Agreement. Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Tacoma Corp. was merged with and into MabVax Therapeutics on July 8, 2014, with MabVax Therapeutics surviving the Merger as a wholly-owned subsidiary of MabVax Therapeutics Holdings. The Merger is intended to qualify as a tax-free reorganization for U.S. Federal income tax purposes.
	On July 7, 2014, the stockholders of MabVax Therapeutics Holdings approved the Merger, and the Merger closed and became effective on July 8, 2014. At the effective date of the Merger: (a) all shares of MabVax Therapeutics Series A preferred stock and all shares of MabVax Therapeutics Series B preferred stock were automatically converted into shares of MabVax Therapeutics Holdings common stock, (b) all outstanding shares of MabVax Therapeutics common stock were converted into and exchanged for shares of MabVax Therapeutics Holdings common stock at an exchange rate calculated in accordance with the methodology set forth in the Merger Agreement, which resulted in 2.223284 shares of MabVax Therapeutics Holdings common stock for every share of MabVax Therapeutics common stock, (c) all outstanding shares of MabVax Therapeutics Series C-1 preferred stock were converted into and exchanged for shares of MabVax Therapeutics Holdings Series A-1 preferred stock at a rate of two shares of MabVax Therapeutics Series C-1 per each share of MabVax Therapeutics Holdings Series A-1 preferred stock, (d) each outstanding MabVax Therapeutics option and warrant to purchase MabVax Therapeutics common stock became options and warrants to purchase shares of MabVax Therapeutics Holdings common stock (and the number of such shares and exercise price was adjusted as calculated in accordance with the methodology set forth in the Merger Agreement), and (e) each outstanding MabVax Therapeutics warrant to purchase MabVax Therapeutics preferred stock was cancelled for no consideration.
	As a result of the consummation of the Merger, as of the closing date, the former stockholders, option holders and warrant holders of MabVax Therapeutics were issued, based on the methodology set forth in the Merger Agreement (which excluded certain out of the money convertible securities and calculated others on a net-exercise or cashless basis under the terms of the convertible securities), approximately 85% of the outstanding shares of MabVax Therapeutics Holdings common stock on a fully diluted basis and the stockholders, option holders and warrant holders of MabVax Therapeutics Holdings prior to the Merger owned approximately 15% of the outstanding shares of MabVax Therapeutics Holdings common stock on a fully diluted basis (such percentages calculated based on the methodology set forth in the Merger Agreement). As a result of the Merger, a change of control of MabVax Therapeutics Holdings occurred.
	For accounting purposes, the Merger is treated as a “reverse acquisition” and MabVax Therapeutics is considered the acquirer. As a result, the historical financial statements of MabVax Therapeutics constitute the historical financial statements of the merged companies. The transaction is considered a business combination as MabVax Therapeutics Holdings is considered an operating entity. For accounting purposes, MabVax Therapeutics is treated as the continuing reporting entity.
	The issuance of shares of our common stock and preferred stock in the Merger was approved by our stockholders in the annual stockholder meeting held on July 7, 2014. Amendments to our amended and restated certificate of incorporation related to an increase in the authorized number of shares of our common stock and preferred stock and a proposed reverse stock split to maintain Nasdaq listing maintenance standards and other transactions contemplated by the Merger Agreement were not approved at this meeting. As a result of our not getting stockholder approval of a proposed reverse stock split at the July 7, 2014 annual stockholders’ meeting, we are seeking additional time through the Nasdaq Exchange’s appeals process to meet all of the listing requirements for the Nasdaq Exchange. In the meantime, shares of our common stock currently trade on the OTCQB market under the stock symbol MBVX. There is no impact on accounting as a result of not getting stockholder approval on all matters presented at the July 7, 2014 annual meeting.
	Preliminary Purchase Price Allocation. The purchase price is based upon the fair value of MabVax Therapeutics Holdings (f.k.a. Telik, Inc.) common stock outstanding of 572,887 shares as of July 8, 2014, multiplied by the stock closing price at July 8, 2014 of $11.20, or approximately $6,416,000. The consideration transferred is based on the market price of MabVax Therapeutics Holdings since management has determined that this was the most reliable measure of fair value, taking into consideration a valuation we received for financial reporting purposes as outlined under the Financial Accounting Standards Board Accounting Standards Codification Topic 805: Business Combination in connection with the Merger.
	The total estimated purchase price of the acquisition as of July 8, 2014 is as follows:
	Purchase Consideration:
	(In thousands)
	Purchase Consideration	$	6,416
	Telik Assets		(1,710	)
	Telik Liabilities		1,452
	Goodwill	$	6,158

Convertible_Preferred_Stock_Co

Convertible Preferred Stock, Common Stock and Warrants	9 Months Ended
	Sep. 30, 2014
Temporary Equity Disclosure [Abstract]	'
Convertible Preferred Stock, Common Stock and Warrants	'
	7. Convertible Preferred Stock, Common Stock and Warrants
	Series C-1 preferred stock purchase agreement
	On February 12, 2014, MabVax Therapeutics entered into a Securities Purchase Agreement (the “MabVax Therapeutics Securities Purchase Agreement”) and issued 3,697,702 shares of MabVax Therapeutics Series C-1 preferred stock, warrants to purchase 2,055,260 shares of MabVax Therapeutics common stock at $3.62 a share (the “MabVax Therapeutics Series C Common Warrants”) and warrants to purchase 1,848,851 shares of MabVax Therapeutics Series C-1 preferred stock at $0.84 a share (the “MabVax Therapeutics Series C Preferred Warrants”), respectively, for aggregate gross proceeds of $3,100,000, less issuance costs of $126,345 (the “MabVax Therapeutics Series C-1 Financing”). The MabVax Therapeutics Series C Common Warrants and Preferred Warrants were exercisable immediately. The MabVax Series C Common Warrants would have expired on February 13, 2022, and the MabVax Therapeutics Series C Preferred Warrants would have expired upon registration of the shares of MabVax Therapeutics common stock (or a successor entity) under the Securities Act. Because the warrants are immediately convertible at the option of the holder, MabVax Therapeutics recorded a deemed dividend of $2,214,911 from the beneficial conversion feature associated with the issuance of the MabVax Series C-1 preferred stock and the MabVax Therapeutics Series C Common Stock Warrants and the MabVax Therapeutics Series C Preferred Stock Warrants.
	In connection with the MabVax Therapeutics Series C-1 Financing, MabVax Therapeutics agreed to use its reasonable best efforts to raise at least an additional $3,000,000 through the sale and issuance of shares of MabVax Therapeutics common stock initially intended to be at $15.08 per share (the “Subsequent Capital Raise”). Substantially all of the investors in the MabVax Therapeutics Series C-1 Financing executed a financing commitment letter (such letters, the “Financing Commitment Letters”) to purchase a pro rata number of shares of MabVax Therapeutics common stock at the purchase price of $15.08 per share, representing in the aggregate at least $750,000, subject to certain terms and conditions, including a condition that MabVax Therapeutics raise at least $3,000,000 from new investors in the Subsequent Capital Raise. In addition, each such commitment letter provided that, in the event that less than $3,000,000 were raised from new investors in the Subsequent Capital Raise and subject to certain terms and conditions, each investor party to such letter was required to purchase shares of MabVax Therapeutics preferred stock to be designated as MabVax Therapeutics Series C-2 convertible preferred stock at $15.08 per share and in the aggregate amount of up to $3,000,000 (the “Backstop Capital Raise”).
	On May 12, 2014, MabVax Therapeutics and certain investors amended the MabVax Therapeutics Securities Purchase Agreement to, among other things, (i) lower the price per share of the Subsequent Capital Raise from $15.08 to approximately $9.93 per share, and (ii) provide that the price per share payable by investors as set forth in the Financing Commitment Letters would henceforth be the lower of (A) $15.08 a share and (B) the lowest price paid in the Subsequent Capital Raise. The price per share of the Backstop Capital Raise was not changed as a result of the amendment. On July 7, 2014, prior to the Merger, MabVax Therapeutics raised over $3.0 million from the sale of common stock and the Backstop Capital Raise was no longer in effect.
	The MabVax Therapeutics Series C-1 preferred stock allowed the holders to require that MabVax Therapeutics redeem their shares of MabVax Therapeutics Series C-1 preferred stock, including any accrued but unpaid dividends, upon the occurrence of any of the following events (each, a “Triggering Event”): (i) the suspension of trading of common stock following registration of such shares, (ii) the failure to issue shares of MabVax Therapeutics common stock upon conversion of any MabVax Therapeutics Series C-1 preferred stock, (iii) the failure to authorize sufficient shares of MabVax Therapeutics common stock to permit the conversion of all outstanding shares of MabVax Therapeutics Series C-1 preferred stock and exercise of all MabVax Therapeutics Series C Common Warrants and MabVax Therapeutics Series C Warrants, (iv) failure to make certain required payments to the holders in excess of $25,000, (v) a default on indebtedness in the aggregate amount of $100,000, (vi) bankruptcy events, (vii) judgments requiring payments in excess of $100,000, (viii) consummation of a change of control with an entity which did not have a class of securities registered for trading, (ix) failure of MabVax Therapeutics to initiate the process of becoming publicly traded (either through a merger into a public company or the filing of a registration statement) within 4 months of the closing of the MabVax Therapeutics Series C-1 Financing, (x) failure to complete such merger within one year or such registration within 4 months of the closing of the MabVax Therapeutics Series C-1 Financing, (xi) issuance of common stock in violation of certain restrictions relating to employee equity, (xii) issuance of debt in violation of any agreement relating to the MabVax Therapeutics Series C-1 Financing, (xiii) failure to convert MabVax Therapeutics Series A preferred stock or MabVax Therapeutics Series B preferred stock on or prior to the date shares of MabVax Therapeutics common stock became publicly tradable, (xiv) any deviation of 20% or more from the annual budget approved by such holders, (xv) any deviation of 5% or more with respect to auditing and investors’ relations expenses, (xvi) failure to deliver the 2013 audited financials within 45 days of the closing of the MabVax Therapeutics Series C-1 Financing, (xvii) any deviation of any line item of the 2013 audited financials from those set forth in the 2013 unaudited financials delivered in connection with the MabVax Therapeutics Series C-1 Financing or (xviii) a breach of any representation, warranty, covenant or other term or condition of any agreement relating to the MabVax Therapeutics Series C-1 Financing. Certain Triggering Events had occurred as of May 9, 2014, but were subsequently waived by the holders of the MabVax Therapeutics Series C-1 preferred stock.
	On July 8, 2014, the date of the Merger, all MabVax Therapeutics Series C-1 preferred stock was converted into shares of MabVax Therapeutics Holdings Series A-1 preferred stock, and the Triggering Events were removed. Because of the removal of the Triggering Events as of the Merger date, the MabVax Therapeutics Holdings Series A-1 convertible preferred stock is presented on the balance sheet as permanent equity as of September 30, 2014.
	Conversion
	After giving effect to the Merger and Reverse Split, the holders of our Series A-1 preferred stock may at any time voluntarily convert each share into a number of fully paid shares of our common stock determined by dividing the liquidation preference (described below) by the initial conversion price of $1.6767 per share. Conversion is subject to (a) proportional adjustment for certain dilutive issuances, splits, combinations and other recapitalizations or reorganizations and (b) a full ratchet anti-dilution adjustment upon issuance of shares of common stock (or securities convertible into shares of common stock) at a price per share (or with a conversion or exercise price per share) less than the applicable conversion price, and subject to customary carve outs and exclusions.
	Under the terms described for a mandatory conversion, all outstanding shares of our Series A-1 preferred stock shall be automatically converted into shares of our common stock upon the affirmative election of the holders of a majority of the issued and outstanding shares of our Series A-1 preferred stock. In the event that the Company does not issue the shares of its common stock upon conversion of any shares of its Series A-1 preferred stock, certain penalties, which may be paid in the form of cash or additional shares of its common stock, will accrue. The number of shares of our common stock issuable upon conversion of our Series A-1 preferred stock held by any particular holder, together with all affiliates of such holder, is capped at 4.99% of the issued and outstanding shares of common stock of the Company. Any shares in excess of such amount will be held in abeyance until such time as the issuance of such shares of common stock would not put such holder, together will all affiliates of such holder, above 4.99%. An individual holder may elect to increase this limit to up to 9.99% effective 61 days after providing notice to the Company.
	Dividends
	The Company’s Series A-1 stockholders are entitled to cumulative dividends on each share held at a rate of 8% per annum on the Stated Value (as defined in the Series A-1 certificate of designations) from and after the first date of issuance of any Series A-1 whether or not declared by the Board and whether or not there are funds legally available for the payment of dividends and these securities are potentially redeemable. Such dividends are in preference to and prior to any payment of any dividend on shares of our Series B preferred stock, our Series C preferred stock or our common stock. If any dividend is declared and paid on any shares of our common stock, Series B preferred stock or Series C preferred stock, a dividend shall be declared and paid on shares of our Series A-1 preferred stock on an “as converted” basis. The Company immediately recognizes the changes in the redemption value as they occur and the carrying value of the security is adjusted to equal what the redemption amount would be as if redemption were to occur at the end of the reporting date based on the conditions that exist as of that date. The value adjustment made to the redemption value for the nine months ended September 30, 2014 was an increase of $307,216.
	Liquidation preference
	In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, our Series A-1 preferred stockholders shall be paid an amount equal to $1.6767 per share, plus all accrued dividends, as adjusted to reflect any stock splits, stock dividends or other recapitalization. In addition, after setting apart or paying in full the Series A-1 preferred stock, and Series B preferred stock liquidation preference, any remaining assets of the Company available for distribution to stockholders, if any, shall be distributed to all stockholders of the Company with holders of our preferred stock participating on an as converted basis without actually converting their preferred stock into common stock.
	In the event that upon liquidation or dissolution, the assets and funds of the Company are insufficient to permit the payment to its preferred stockholders of the full preferential amounts, then the entire assets and funds of the Company legally available for distribution are to be distributed ratably first to the holders of shares of our Series A-1 preferred stock, second to holders of our Series B preferred stock and third on a pro rata basis to all stockholders of the Company on an as-converted basis.
	Voting rights
	Each holder of our Series A-1 preferred stock is entitled to the number of votes equal to the number of shares of our common stock into which such holder’s shares are convertible. In addition, the consent of the Required Holders (as defined in the Series A-1 preferred stock certificate of designations) is required in certain circumstances.
	Exercise of MabVax Therapeutics Series C Preferred Warrants
	On July 7, 2014, MabVax Therapeutics received $1.5 million in exchange for the exercise by holders of the MabVax Therapeutics Series C Preferred warrants to purchase 1,827,979 shares of MabVax Therapeutics Series C-1 preferred stock.
	MabVax Therapeutics Series A and MabVax Therapeutics Series B preferred stock (Pre-Merger MabVax Therapeutics Issuances)
	As of December 31, 2013, the holders of shares of MabVax Therapeutics Series A preferred stock and MabVax Therapeutics Series B preferred stock were entitled to cumulative cash dividends of 8% per annum, when and if declared by the MabVax Therapeutics Board of Directors. Such dividends would have been in preference to and prior to any payment of any dividend on shares of MabVax Therapeutics common stock. Cumulative preferred stock dividends, when and if declared, for the MabVax Therapeutics Series A preferred stock totaled approximately $2,115,000 and the MabVax Therapeutics Series B preferred stock totaled approximately $431,000, as of December 31, 2013, and were reduced to zero in February 2014 as a result of the MabVax Therapeutics Series C-1 Preferred Stock Financing.
	In January 2014, holders of warrants to purchase shares of MabVax Therapeutics Series B preferred stock exercised their rights to purchase 194,281 shares of MabVax Therapeutics Series B preferred stock for proceeds of approximately $2,000.
	In February 2014, the holders of MabVax Therapeutics Series A preferred stock and MabVax Therapeutics Series B preferred stock waived any rights to all prior accrued dividends they may have had a right to receive and amended the MabVax Therapeutics certificate of incorporation to eliminate their right to accrue dividends in the future as an inducement to buyers in the MabVax Therapeutics Series C-1 Preferred Stock Financing. The effect of this change reduced the liquidation preference for the MabVax Therapeutics Series A preferred stock by $2,114,818 and the MabVax Therapeutics Series B preferred stock by $430,944.
	No dividends were ever declared by the MabVax Therapeutics Board of Directors since MabVax Therapeutics’ inception on either of the MabVax Therapeutics Series A preferred stock or the MabVax Therapeutics Series B preferred stock.
	Removal of Redemption Rights – As of December 31, 2013, the holders of a majority interest of the MabVax Therapeutics Series A preferred stock and MabVax Therapeutics Series B preferred stock held a right to redeem (the “MabVax Therapeutics Redemption Right”), at any time on or after the fifth anniversary of the issuance date, upon request of at least 60% of the holders thereof, all of their preferred stock at a redemption price of $6.17 and $6.82 per share of MabVax Therapeutics Series A preferred stock and MabVax Therapeutics Series B preferred stock, respectively, exclusive of dividends. Due to these terms, MabVax Therapeutics classified all of the MabVax Therapeutics preferred stock as mezzanine equity (outside of permanent equity) as of December 31, 2013. In March 2014, the majority of holders or more than 60% of the MabVax Therapeutics Series A preferred stock and MabVax Therapeutics Series B preferred stock agreed by letter commitment to MabVax Therapeutics to relinquish the MabVax Therapeutics Redemption Right, and MabVax Therapeutics reclassified the presentation on the condensed consolidated balance sheets as permanent equity following the agreement.
	Liquidation preference – As of December 31, 2013, in the event of any voluntary or involuntary liquidation, dissolution or winding up of MabVax Therapeutics, the MabVax Therapeutics Series A preferred stockholders and MabVax Therapeutics Series B preferred stockholders were entitled to be paid an amount equal to $6.17 and $6.82 per share, respectively, plus all declared and unpaid dividends, as adjusted to reflect any stock splits, stock dividends or other recapitalization. In addition, after setting apart or paying in full the MabVax Therapeutics Series A preferred stock and MabVax Therapeutics Series B preferred stock liquidation preference, any remaining assets of MabVax Therapeutics available for distribution to its stockholders would have been distributed to all stockholders of MabVax Therapeutics with holders of MabVax Therapeutics preferred stock participating on an as converted basis without actually converting their MabVax Therapeutics preferred stock into shares of MabVax Therapeutics common stock. In the event that upon liquidation or dissolution, the assets and funds of MabVax Therapeutics would have been insufficient to permit the payment to MabVax Therapeutics preferred stockholders of the full preferential amounts, then the entire assets and funds of MabVax Therapeutics legally available for distribution were to be distributed ratably first to the holders of MabVax Therapeutics Series B preferred stock, second to the holders of MabVax Therapeutics Series A preferred stock and third on a pro rata basis to all stockholders of MabVax Therapeutics on an as-converted basis.
	MabVax Therapeutics Holdings Series B Preferred Stock
	On May 12, 2014 (the “Closing Date”), MabVax Therapeutics Holdings entered into a securities purchase agreement (the “Series B Purchase Agreement”) with certain purchasers the “Purchasers” pursuant to which MabVax Therapeutics Holdings agreed to issue and sell to the Purchasers, subject to customary closing conditions, an aggregate of 1,250,000 shares of MabVax Therapeutics Series B preferred stock and warrants (the “Series B Common Warrants”) to purchase up to an additional 78,125 shares of MabVax Therapeutics Holdings common stock, with an aggregate purchase price of $2,500,000, or $2.00 for each share of our Series B preferred stock and related Series B Common Warrant (such transaction collectively, the “Series B Private Placement”). The closing of the Series B Private Placement took place on the Closing Date.
	On May 8, 2014, MabVax Therapeutics Holdings filed a certificate of designation for the MabVax Therapeutics Holdings Series B preferred stock with the Secretary of State of the State of Delaware. The certificate of designations authorized 1,250,000 shares of Series B preferred stock. Holders of MabVax Therapeutics Series B preferred stock (the “Holders”) are entitled to cumulative dividends on each share held at a rate of 8% per annum on the Stated Value (as defined in the certificate of designations). Upon a liquidation event, the Holders are entitled to a liquidation preference per share, prior to any distribution of the Company’s assets to the holders of its common stock, in an amount equal to the Stated Value plus accrued and unpaid dividends. After payment to the Holders of the full preferential amount, the Holders will, on a pari passu basis with the holders of the Company’s common stock, participate in the distribution of any remaining assets of the Company, subject to certain limitations. Each Holder may elect to convert their Series B preferred stock into shares of the Company’s common stock at the applicable conversion rate in effect at the time of such conversion. However, the Company shall not effect conversion of the Series B preferred stock to the extent such conversion would result in the beneficial owner acquiring beneficial ownership of more than 4.99% of the Company’s outstanding common stock post-conversion, including any shares of its common stock issuable upon exercise or conversion of other convertible securities held by such beneficial owner. The Company obtained stockholder approval for the securities being issued in the Series B Private Placement at the annual stockholder meeting held on July 7, 2014. The conversion rate is subject to full ratchet anti-dilution protection upon certain dilutive issuances of our common stock or convertible securities of the Company. Such conversion price will be subject to adjustment from and after the earlier of: (i) the date that some or all of the Registerable Securities (as defined below) have become registered pursuant to an effective registration statement and (ii) six months after the Closing Date at which time the conversion price of the Series B preferred stock shall equal the lower of (a) the initial conversion price and (b) 90% of the average of the 10 lowest weighted average prices of the Company’s common stock during the 20 trading days immediately preceding applicable date of the conversion, of which neither event had occurred as of September 30, 2014. The Holders may also require the Company to redeem their shares of Series B preferred stock prior to a change of control, as set forth in the certificate of designations. The certificate of designations further provides that the Holders are entitled to certain participation rights on issuances by the Company to holders of common stock in order to maintain their proportionate ownership, subject to certain customary exclusions, such as issuances pursuant to Company option plans, and in connection with the Merger.
	The Series B Common Warrants become exercisable six months from the Closing Date, expire five years from the Closing Date and may be exercised for cash or otherwise may be net-exercised. The Series B Common Warrants will initially have a per share exercise price of $26.64. On the 60th day following the earlier of (i) the date all of the shares underlying the Warrants become registered pursuant to an effective registration statement and (ii) six months following the Closing Date (in each case, the “Reset Date”), the exercise price shall be reset to equal the lower of (i) the current exercise price and (ii) 90% of the average of the 10 lowest weighted average prices of Common Stock during the 20 trading days immediately preceding the Reset Date. The exercise price is subject to full ratchet anti-dilution adjustment for any issuances of common stock and convertible securities for common stock below the current conversion price, consistent with the terms of the Series B preferred stock.
	In connection with the Series B Private Placement, the Company also entered into a Registration Rights Agreement with the Purchasers (the “Series B Registration Rights Agreement”). Pursuant to the Series B Registration Rights Agreement, the Company will agree to file a registration statement with the SEC covering resales of the Warrant Shares and the shares issuable upon conversion of the Series B preferred stock (together, the “Series B Registerable Securities”) by the Purchasers no later than 60 days following the Closing Date, and to use its commercially reasonable best efforts to have such registration statement declared effective as soon as practicable. The Company will bear all expenses of such registration of the resale of the Registerable Securities. On September 3, 2014, the Required Holders (as defined in the Series B preferred stock certificate of designations) temporarily waived the 60 day registration deadline for a five day period.
	As a result of the Series B Warrants’ anti-dilution provision, the Series B Warrants are recorded as a current liability on our condensed consolidated balance sheet. The outstanding warrant was valued at $341,301 and $567,885 as of September 30, 2014, and July 8, 2014 or the acquisition date, respectively. Our outstanding warrants are revalued on each balance sheet date, with changes in the fair value between reporting periods recorded in the condensed consolidated statements of operations.
	Warrants are valued using Black-Scholes-Merton model utilizing probability of certain events that could cause repricing the warrants, such as a demand letter to register the shares. The expected life is based on the term of the warrants. We use our historical volatility in developing our estimate of expected volatility. The fair value of warrants is estimated using the following assumptions, which, except for risk-free interest rate, are Level 3 inputs:
	The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of September 30, 2014 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value:
					Basis of Fair Value Measurement at September 30, 2014
		September 30, 2014			Quoted Prices in			Significant Other		Significant
					Active Markets			Observable		Unobservable
					for Identical			Inputs (Level 2)		Inputs (Level 3)
					Assets (Level 1)
	Financial assets:
	Money market funds	$	25,131		$	25,131		$	—	$	—
	Total financial assets	$	25,131		$	25,131		$	—	$	—
	Financial liabilities:
	Warrants	$	341,301		$	—		$	—	$	341,301
	Total financial liabilities	$	341,301		$	—		$	—	$	341,301
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of December 31, 2013, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.
					Basis of Fair Value Measurement at December 31, 2013
		December 31, 2013			Quoted Prices in			Significant Other		Significant
					Active Markets			Observable		Unobservable
					for Identical			Inputs (Level 2)		Inputs (Level 3)
					Assets (Level 1)
	Financial assets: (presented as cash equivalents):
	Money market funds	$	350,557		$	350,557		$	—	$	—
	Total financial assets	$	350,557		$	350,557		$	—	$	—
	The changes in the value of the warrant liability during the nine months ended September 30, 2014 were as follows:
	Fair value – beginning of period	$	—
	Fair value on acquisition		567,885
	Change in fair value		(226,584	)
	Fair value – end of period	$	341,301
	There were no transfers between Level 1 and Level 2 measurements in the three and nine months ended September 30, 2014 and in the year ended December 31, 2013.
	Warrant liability valuation assumptions
		As of			As of
		September 30, 2014			July 8, 2014
Risk-free interest rate		1.7	%		1.6	%
Dividend yield		—	%		—	%
Expected volatility		87.2	%		101.6	%
Expected life of options, in years		4.61			4.9
Market price for common stock	$	6.5		$	11.6
Warrant exercise price, adjusted	$	6.21		$	26.64
Warrant liability	$	341,301		$	567,885
Exchange Agreement and Series C Preferred Stock
On September 3, 2014, MabVax Therapeutics Holdings and certain holders of its issued and outstanding common stock entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to which such holders agreed to exchange 118,970 shares of MabVax Therapeutics Holdings common stock for an aggregate of approximately 118,970 shares of newly designated MabVax Therapeutics Holdings Series C preferred stock, convertible into 148,713 shares of common stock.
As contemplated by the Exchange Agreement and as approved by the Board of Directors, the Company filed with the Secretary of State of the State of Delaware a certificate of designations for the Series C preferred stock, on September 3, 2014. Holders of the Series C preferred stock are entitled to vote on an as converted basis on matters presented to the Company’s stockholders and, upon liquidation, share in distributions on a pari passu basis with the holders of the Company’s common stock in amounts available for distribution following payments required to be made to the holders of the Series A-1 preferred stock and Series B preferred stock. Each share of Series C preferred stock is convertible into 1.25 shares of our common stock subject to adjustment and the conversion limitations set forth in the Series C certificate of designations. When and as declared by the Board of Directors, the holders of the Series C preferred stock shall be entitled to receive dividends on an as converted basis (without regard to any limitations on conversion) with the holders of the Company’s common stock.
The terms of the Exchange Agreement and Series C Certificate of Designations were determined by arms-length negotiation between the parties. The shares of common stock issuable pursuant to the Exchange Agreement have been, or will be, upon settlement, issued in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act for securities exchanged by an issuer and an existing securityholder where no commission or other remuneration is paid or given directly or indirectly by the issuer for soliciting such exchange.
MabVax Common Stock Financing
From June 27 to July 7, 2014, MabVax Therapeutics Holdings issued approximately 326,000 shares of common stock for aggregate proceeds of approximately $2,893,000, net of issuance costs of approximately $148,000, in a private placement transaction (the “MabVax Common Stock Private Placement”), pursuant to Common Stock Purchase Agreements by and among MabVax Therapeutics and certain institutional investors party thereto (the “MabVax Purchase Agreements”). Pursuant to the MabVax Purchase Agreements, MabVax Therapeutics agreed to issue the purchasers participating in closings held under the MabVax Common Stock Private Placement prior to the closing of the Merger additional “anti-dilution” shares of MabVax Therapeutics common stock, for no additional consideration should MabVax Therapeutics sell shares of its common stock in the future (subject to certain customary exceptions, such as upon the conversion or exercise of then outstanding convertible securities, the securities issued in the Merger and issuances under the MabVax Therapeutics option plan) at a price lower than $9.14 per share prior to the first to occur of (x) December 31, 2015 and (y) the date on which MabVax Therapeutics raises an aggregate of $10,000,000. The number of additional shares would be calculated on a weighted average based on the price per share of equity securities sold by MabVax Therapeutics following the initial closing of the MabVax Common Stock Private Placement and in no event would a purchaser be issued a number of additional shares of MabVax Therapeutics common stock in excess of 33% of the number of shares initially purchased by such purchaser and held as of the date of any anti-dilution adjustment. These shares of MabVax Therapeutics common stock issued in the MabVax Common Stock Private Placement were converted into shares of MabVax Therapeutics Holdings common stock in connection with the Merger. MabVax Therapeutics’ obligations with respect to the anti-dilution provisions in the Merger were assumed by MabVax Therapeutics Holdings, and these provisions now apply to sales of MabVax Therapeutics Holdings common stock.
Temporary Waiver of Warrant Exercise Period
On the effective date of the Merger and pursuant to the Merger Agreement, MabVax Therapeutics Holdings issued its securities to the holders of MabVax Therapeutics in exchange for securities owned by MabVax Therapeutics’ securityholders, as follows: (i) an aggregate of approximately 1,168,700 shares of MabVax Therapeutics Holdings common stock, (ii) an aggregate of 2,762,841 shares of MabVax Therapeutics Holdings Series A-1 preferred stock, par value $0.01 per share, convertible into an aggregate of approximately 1,609,000 shares of MabVax Therapeutics Holdings common stock as of the effective date of the Merger, with such powers, designations, preferences and other rights as set forth in the Series A-1 certificate of designation, (iii) warrants to purchase up to an aggregate of approximately 2,055,000 shares of MabVax Therapeutics Holdings common stock, with an exercise price of $3.62 per share and expiring on July 10, 2023 (the “Merger Warrants”), and (iv) options to purchase up to approximately 243,000 shares of MabVax Therapeutics Holdings common stock.
The preamble of the Merger Warrants contains limitations prohibiting the Merger Warrant holders from exercising the Merger Warrants prior to the one year anniversary of the effective date of the Merger, or July 8, 2015. On September 3, 2014, the Company sent a letter to the holders of the issued and outstanding Merger Warrants (the “Waiver Letter”), waiving, on a limited basis from September 3 through September 12, 2014, the requirement set forth in the preamble of the Merger Warrants that the Merger Warrants may not be exercised until July 8, 2015 and permitting the Merger Warrants to be exercised, either through payment of the exercise price or on a net “cashless” basis, at any time during the period commencing on the date of the letter and ending on and including September 12, 2014 (the “Waiver Period”). The Waiver Letter also provides that, with respect to exercises pursuant to the Waiver Letter during the Waiver Period, the number of shares of common stock issuable upon cashless exercise shall be determined in accordance with the formula set forth in the Waiver Letter rather than the formula set forth in Section 1(d) of the Merger Warrant.
As of September 30, 2014, 276,041 shares of the Company’s common stock were issued pursuant to the exercise of Merger Warrants in accordance with the terms of the Waiver Letter.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	8. Related Party Transactions
	In February 2014, MabVax Therapeutics issued approximately 44,000 shares of common stock to related parties in settlement of $240,000 in related party liabilities for consulting services.
	In connection with the Merger, MabVax Therapeutics Holdings (f.k.a. Telik, Inc.) signed separation agreements in May 2014 with nine employees and agreed to pay severances and health benefits upon closing of the Merger subject to certain provisions in the agreement. The total in severance and benefits costs to be paid out subsequent to the Merger is approximately $748,000. At September 30, 2014, the severance and benefits accrued is approximately $239,000.

Stockbased_Activity

Stock-based Activity	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-based Activity	'
	9. Stock-based Activity
	Stock-based Compensation
	Total estimated stock-based compensation expense, related to all of the Company’s stock-based payment awards recognized under ASC 718, “Compensation—Stock Compensation” was comprised of the following:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014		2013
	Research and development	$	32,082		$	41,652		$	109,509	$	125,097
	General and administrative		111,650			39,916			401,090		119,886
	Total stock-based compensation expense	$	143,732		$	81,568		$	510,599	$	244,983
	Stock-based Award Activity
	The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2014:
		Options			Weighted-Average
		Outstanding			Exercise
					Price
	Outstanding at December 31, 2013		152,017		$	1.2
	Granted		90,876			8.47
	Exercised		—			—
	Forfeited/cancelled/expired		—			—
	Outstanding and expected to vest at September 30, 2014		242,893			3.92
	Vested and exercisable at September 30, 2014		152,017		$	1.2
	The total unrecognized compensation cost related to unvested stock option grants as of September 30, 2014 was $838,737 and the weighted average period over which these grants are expected to vest is 2.7 years. The Company has assumed a forfeiture rate of zero. The weighted average remaining contractual life of stock options outstanding at September 30, 2014 is 8.2 years.
	None of the stock options granted to employees during the nine month period ended September 30, 2014 were vested at September 30, 2014, as they generally vest over a four year period and vesting does not start until the one-year anniversary of the grant date. During the first nine months of 2014, the Company granted five new board members appointed in connection with the Merger an aggregate of 55,580 in stock options, which were immediately vested on the grant date.
	Valuation Assumptions
	The Company used the Black-Scholes-Merton option valuation model, or the Black-Scholes model, to determine the stock-based expense recognized under ASC 718. The Company’s expected stock-price volatility assumption was based solely on the weighted average of the historical and implied volatility of comparable companies whose share prices are publicly available. The expected term of stock options granted was based on the simplified method in accordance with Staff Accounting Bulletin No. 110, or SAB 110, as the Company’s historical share option exercise experience did not provide a reasonable basis for estimation. The risk-free interest rate was based on the U.S. Treasury yield for a period consistent with the expected term of the stock award in effect at the time of the grant.
		Nine Months Ended			Nine Months Ended
		September 30,			September 30,
		2014			2013
	Risk-free interest rate		1.4 to 2	%		0.6	%
	Dividend yield		—	%		—	%
	Expected volatility		93 to 100	%		86	%
	Expected life of options, in years		5 and 6.25			6.25
	Weighted-average grant date fair value	$	4.73		$	11.84
	Because the Company had a net operating loss carryforward as of September 30, 2014, no tax benefits for the tax deductions related to stock-based compensation expense were recognized in the Company’s Condensed Consolidated Statements of Operations. Additionally, no stock options were exercised in the three and nine months ended September 30, 2014 and 2013.
	Common stock reserved for future issuance
	Common stock reserved for future issuance consists of the following at September 30, 2014:
	Common stock reserved for conversion of preferred stock and warrants		1,916,400
	Common stock options outstanding		242,893
	Authorized for future grant or issuance under the Stock Plan		326,431
	Total		2,485,724

Net_Loss_per_Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	10. Net Loss per Share
	The Company calculates basic and diluted net loss per share using the weighted-average number of shares of common stock outstanding during the period.
	When the Company is in a net loss position, it excludes from the calculation of diluted net loss per share all potentially dilutive stock options, preferred stock and warrants, and the diluted net loss per share is the same as the basic net loss per share for such periods. If the Company was to be in a net income position, the weighted-average number of shares used to calculate the diluted net income per share would include the potential dilutive effect of in-the-money securities, as determined using the treasury stock method.
	The table below presents the potentially dilutive securities that would have been included in the calculation of diluted net loss per share if they were not antidilutive for the periods presented.
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Stock options		123,879		51,178		108,167		49,478
	MabVax Series A preferred stock		—		265,749		183,980		265,749
	MabVax Series B preferred stock		—		203,645		199,489		172,134
	MabVax Series C-1 preferred stock		93,762		—		576,654		—
	Series A-1 preferred stock		1,451,913		—		489,289		—
	Series B preferred stock		158,339		—		81,779		—
	Series C preferred stock		43,644		—		14,708		—
	Total		1,871,537		520,572		1,654,066		487,361

Contracts_and_Agreements

Contracts and Agreements	9 Months Ended
	Sep. 30, 2014
Health Care Organizations [Abstract]	'
Contracts and Agreements	'
	11. Contracts and Agreements
	$1.5 Million Contract Award
	On August 25, 2014, MabVax Therapeutics was awarded a $1.5 million contract for the Phase 2 portion of a Small Business Innovation Research (“SBIR”) contract from the National Cancer Institute (“NCI”). The contract is intended to support a major portion of the preclinical work being conducted by MabVax Therapeutics, together with its collaboration partner, MSKCC to develop a novel Positron Emission Tomography (“PET”) imaging agent for detection and assessment of pancreatic cancer.
	Juno Therapeutics Option Agreement
	On August 29, 2014, MabVax Therapeutics entered into an Option Agreement (the “Option Agreement”) with Juno Therapeutics, Inc. (“Juno”). Pursuant to the Option Agreement, MabVax Therapeutics granted Juno the option to obtain an exclusive, world-wide, royalty-bearing license (the “License”) authorizing Juno to develop, make, have made, use, import, have imported, sell, have sold, offer for sale and otherwise exploit certain patents MabVax Therapeutics developed with respect to fully human antibodies with binding specificity against human GD2 or sialyl Lewis A antigens (the “Patents”) and certain MabVax Therapeutics controlled biologic materials. Juno may exercise its option to purchase the License until the earlier of June 30, 2016 or 90 days from the date MSKCC completes its research with respect to the Patents in accordance with the terms of agreements by and between MSKCC and MabVax Therapeutics.
	The Option Agreement may be terminated by either party (i) upon material breach of the other party if the breach is not cured within 30 days, or (ii) with 60 days’ prior written notice in the event the other party becomes the subject of a voluntary or involuntary petition in bankruptcy. Juno may terminate the Option Agreement at any time upon 30 days’ prior written notice. MabVax Therapeutics may terminate the Option Agreement if Juno, or any Juno employee or affiliate, is a party to any action or proceeding in which Juno, or any Juno employee or affiliate, opposes the Patents or otherwise seeks a determination that any of the Patents are invalid or unenforceable if Juno, or as applicable, its employee and/or affiliate, fails to discontinue its involvement in such an action within 10 days of receiving notice from MabVax Therapeutics.
	As consideration for the grant of the exclusive option to purchase the License, Juno has agreed to pay MabVax Therapeutics a one-time up-front option fee in the low five figures. Should the option be exercised, MabVax Therapeutics would expect to negotiate with Juno to pay amounts that include MabVax Therapeutics license fees, milestone payments, and royalty-based compensation in connection with entering into a License. The terms of the License including the financial terms are expected to be agreed upon at a future date.

Commitments_and_contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and contingencies	'
	12. Commitments and contingencies
	Litigation
	On May 30, 2014, a class action lawsuit was commenced in Santa Clara County Superior Court, State of California, on behalf of Cadillac Partners and others similarly situated, naming as defendants, MabVax Therapeutics, the Company and the company’s directors, Hudson Bay Capital Management LP, Bio IP Ventures LLC, Hudson Bay Master Fund Ltd., and Hudson Bay IP Opportunities Master Fund LP. The suit alleged the defendants breached certain fiduciary duties, or aided and abetted a breach of fiduciary duties, in connection with the Company’s Merger with MabVax Therapeutics. In support of their purported claims, the plaintiff alleged, among other things, that the Company’s board has historically failed to fulfill its fiduciary duty to its stockholders, and claiming with respect to the Series B Private Placement and the Merger, the such transactions involved an inadequate sales process and included preclusive deal protection devices, and that the Company’s board of directors would receive personal benefits not available to its public stockholders as a result of the Merger. The plaintiff sought to enjoin the Merger and obtain damages as well as attorneys’ and expert fees and costs.
	On June 29, 2014, the parties entered into a Stipulation and Settlement (the “Settlement”), pursuant to which the Company agreed to file with the SEC certain supplemental disclosures in connection with the Merger. The Settlement is subject to certain confirmatory discovery to be undertaken by the plaintiff and to the parties’ agreement on the payment of the plaintiff’s attorneys’ fees and expenses.
	On July 16, 2014, the Company and all other parties to the litigation entered into an agreement which, if consummated, will settle the litigation (the “Proposed Settlement”). Among many other terms, under the Proposed Settlement the Company and all defendants will receive a broad release of any and all claims pertaining to the Series B Private Placement, the Merger, the prior disclosure and a wide variety of other matters. The Proposed Settlement also calls for the parties to ask the court to, among other things, enter orders enjoining other stockholders from bringing similar actions, certifying the putative settlement class, and approving the Proposed Settlement as a fair, final, and binding resolution of the litigation. Under the Proposed Settlement, the Company and the other defendants have expressly denied the allegations of the complaint and denied engaging in any other misconduct, nor will any of them make any payment or in any respect amend the negotiated terms of the since-consummated Series B Private Placement and Merger. Finally, under the Proposed Settlement, the Company and the other defendants have not agreed to pay any legal fees, or reimburse any expenses, allegedly incurred by the plaintiffs who filed the complaint; instead, the Company expects that counsel for those plaintiffs will present any such disputed claim for legal fees and expenses to the court for resolution.
	Operating Leases
	In connection with the Merger, the Company recorded a $590,504 contingent lease termination fee, in connection with the termination by MabVax Therapeutics Holdings (f.k.a Telik, Inc.) of the master lease and sublease of the Porter Drive Facility, which is payable to ARE-San Francisco No. 24 (“ARE”), if the Company receives $15 million or more in additional financing in the aggregate, but otherwise forgiven.
	Restructuring Plan upon Closing of the Merger
	In connection with the Merger, the Company signed separation agreements in May 2014 with nine employees and agreed to pay severances and health benefits upon closing of the Merger subject to certain provisions in the agreements. The total in severance and benefits costs being paid out is approximately $748,000, of which approximately $239,000 remains as of September 30, 2014.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	13. Subsequent Events
	Temporary Waiver of Warrant Exercise Period
	On October 3, 2014, following the Company’s delivery on September 30, 2014 of a second letter to the holders of the issued and outstanding Merger Warrants (the “Waiver Extension Letter”), waiving, on a limited basis for a four day period, the requirement set forth in the preamble of the Merger Warrants that the Merger Warrants may not be exercised until July 8, 2015 and permitting the Merger Warrants to be exercised, either through payment of the exercise price or on a net “cashless” basis, at any time during the period commencing on the date of the letter and ending on and including October 3, 2014( the “Waiver Extension Period”). The Waiver Extension Letter also provides that, with respect to exercises pursuant to the Waiver Extension Letter during the Waiver Extension Period, the number of shares of the Company’s common stock issuable upon cashless exercise shall be determined in accordance with the formula set forth in the Waiver Extension Letter rather than the formula set forth in Section 1(d) of the Merger Warrant.
	The Company’s management issued the temporary waiver of the warrant exercise period limitation for a second time with the intention of gradually increasing the number of its publicly held shares in furtherance of the Company’s continued efforts to satisfy NASDAQ’s Initial Listing Standards and regain trading eligibility for shares of its common stock on the NASDAQ Capital Market. Shares of the Company’s common stock issued upon exercise of the Merger Warrants will not be registered for resale during the Waiver Extension Period and will be subject to resale restrictions per Rule 144 as promulgated by the Securities Act.
	The foregoing descriptions of the Merger Agreement, the Merger Warrants and the Waiver Extension Letter are not complete and are subject to, and qualified in their entirety by, the full text of such documents which are filed as exhibits to this Quarterly Report on Form 10-Q.
	On October 3, 2014, 314,118 additional shares of the Company’s common stock were issued pursuant to the exercise and delivery of 504,264 Merger Warrants in accordance with the terms of the Waiver Letter and the Waiver Extension Letter.
	Registration of Common Stock Issuable upon Conversion of Series A-1 Preferred Stock
	On October 14, 2014, the Company filed an Amendment No. 1 to a Registration Statement on Form S-1 (the “Form S-1”) that was initial filed on September 29, 2014, for the purpose of registering additional shares of MabVax Therapeutics Holdings common stock issuable upon conversion of outstanding shares of MabVax Therapeutics Holdings Series A-1 preferred stock. The Form S-1, as amended, to register 1,615,070 shares of common stock, was declared effective by the SEC at 4:00 p.m. Easter Standard Time on November 12, 2014.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Nature of operations and basis of presentation	'
	MabVax Therapeutics Holdings, Inc. (f.k.a. Telik, Inc. and referred to herein as “MabVax Therapeutics Holdings” or the “Company”) (OTCQB: MBVX) was incorporated in the state of Delaware on October 20, 1988. On July 8, 2014, Tacoma Acquisition Corp., a Delaware corporation and wholly owned subsidiary of MabVax Therapeutics Holdings (“Tacoma Corp.”) merged with MabVax Therapeutics, Inc., a Delaware corporation (“MabVax Therapeutics”) pursuant to an Agreement and Plan of Merger, dated May 12, 2014, by and among MabVax Therapeutics Holdings, Tacoma Corp. and MabVax Therapeutics, as amended by that certain Amendment No. 1 to the Merger Agreement, dated June 30, 2014, by and among the parties thereto and by that certain Amendment No. 2 to the Merger Agreement, dated July 7, 2014, by and among the parties thereto (such agreement as amended, the “Merger Agreement”; such merger, the “Merger”). Unless the context otherwise requires, references to “we,” “our,” “us,” or the “Company” in this Quarterly Report mean MabVax Therapeutics Holdings on a condensed consolidated financial statement basis with our wholly-owned subsidiary following the Merger, MabVax Therapeutics, as applicable. On October 9, 2014 FINRA approved our stock symbol change request and the Company began trading under the symbol MBVX (OTCQB: MBVX) on October 10, 2014.
	The balance sheet data at December 31, 2013, has been derived from audited financial statements at that date. It does not include, however, all of the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. Par value and additional paid-in capital for December 31, 2013 has been restated to reflect the par value for shares post-merger and the September 8, 2014 8-for-1 Reverse Split (as defined below).
	We are a clinical stage biopharmaceutical company engaged in the discovery, development and commercialization of proprietary human monoclonal antibody products and vaccines for the treatment of a variety of cancers. We have discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Therapeutic vaccines under development were discovered at Memorial Sloan Kettering Cancer Center (“MSKCC”), and are exclusively licensed to MabVax Therapeutics. We operate in only one business segment.
	We are continuing to evaluate the technology and development programs that were under way at MabVax Therapeutics Holdings prior to the Merger and plan to continue developing MabVax Therapeutics’ pre-Merger pipeline. We currently expect that we will cease patent applications and patent prosecutions for the Telintra development program in place at MabVax Therapeutics Holdings prior to the Merger.
	We have incurred net losses since inception and expect to incur substantial losses for the foreseeable future as the Company continues research and development activities. To date, we have funded operations primarily through government grants, the sale of preferred stock, equity securities, non-equity payments from collaborators and interest income. The process of developing the Company’s products will require significant additional research and development, preclinical testing and clinical trials, as well as regulatory approval. We expect these activities, together with general and administrative expenses, to result in substantial operating losses for the foreseeable future. We will not receive revenue unless the Company or its collaborative partners complete clinical trials, obtain regulatory approval and successfully commercialize one or more products; or the Company licenses its technology after achieving one or more milestones of interest to a potential partner.
	The accompanying unaudited condensed consolidated financial statements were prepared using GAAP for interim financial information and the instructions to Regulation S-X. Accordingly, these financial statements do not include all information or notes required by GAAP for annual financial statements and should be read in conjunction with the Audited Financial Statements of MabVax Therapeutics for the period from May 5, 2006 (inception) through December 31, 2013, filed with our Definitive Proxy Statement on Form DEFM14A on June 3, 2014.
	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	The Company has historically reported as a development stage Company. In the period ended June 30, 2014, the Company elected to early adopt FASB Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements.” The adoption of this ASU allows the Company to remove the inception to date information and all references to development stage.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606). ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. Additionally, this update supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition-Construction-Type and Production-Type Contracts.” The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It is effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities may choose from two adoption methods, with certain practical expedients. We are currently reviewing this standard to assess the impact on the Company’s future financial statements and evaluating the available adoption methods.
	In June 2014, the FASB issued ASU No. 2014-12, “Compensation—Stock Compensation” (Topic 718): “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. ASU No. 2014-12 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. We are currently reviewing this standard to assess the impact on the Company’s future financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, (“ASU 2014-15”), “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern”. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. Certain disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of the updated standard on the financial statements and disclosures.

Merger_with_MabVax_Therapeutic1

Merger with MabVax Therapeutics, Inc. (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Schedule of Estimated Purchase Price of Acquisition	'
	The total estimated purchase price of the acquisition as of July 8, 2014 is as follows:
	Purchase Consideration:
	(In thousands)
	Purchase Consideration	$	6,416
	Telik Assets		(1,710	)
	Telik Liabilities		1,452
	Goodwill	$	6,158

Convertible_Preferred_Stock_Co1

Convertible Preferred Stock, Common Stock and Warrants (Tables)	9 Months Ended
	Sep. 30, 2014
Temporary Equity Disclosure [Abstract]	'
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis	'
	The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of September 30, 2014 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value:
					Basis of Fair Value Measurement at September 30, 2014
		September 30, 2014			Quoted Prices in			Significant Other		Significant
					Active Markets			Observable		Unobservable
					for Identical			Inputs (Level 2)		Inputs (Level 3)
					Assets (Level 1)
	Financial assets:
	Money market funds	$	25,131		$	25,131		$	—	$	—
	Total financial assets	$	25,131		$	25,131		$	—	$	—
	Financial liabilities:
	Warrants	$	341,301		$	—		$	—	$	341,301
	Total financial liabilities	$	341,301		$	—		$	—	$	341,301
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of December 31, 2013, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.
					Basis of Fair Value Measurement at December 31, 2013
		December 31, 2013			Quoted Prices in			Significant Other		Significant
					Active Markets			Observable		Unobservable
					for Identical			Inputs (Level 2)		Inputs (Level 3)
					Assets (Level 1)
	Financial assets: (presented as cash equivalents):
	Money market funds	$	350,557		$	350,557		$	—	$	—
	Total financial assets	$	350,557		$	350,557		$	—	$	—
Schedule of Changes in the Value of the Warrant Liability	'
	The changes in the value of the warrant liability during the nine months ended September 30, 2014 were as follows:
	Fair value – beginning of period	$	—
	Fair value on acquisition		567,885
	Change in fair value		(226,584	)
	Fair value – end of period	$	341,301
Schedule of Warrant Liability Valuation Assumptions	'
	Warrant liability valuation assumptions
		As of			As of
		September 30, 2014			July 8, 2014
	Risk-free interest rate		1.7	%		1.6	%
	Dividend yield		—	%		—	%
	Expected volatility		87.2	%		101.6	%
	Expected life of options, in years		4.61			4.9
	Market price for common stock	$	6.5		$	11.6
	Warrant exercise price, adjusted	$	6.21		$	26.64
	Warrant liability	$	341,301		$	567,885

Stockbased_Activity_Tables

Stock-based Activity (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-based Compensation	'
	Three Months Ended						Nine Months Ended
	September 30,						September 30,
		2014			2013			2014		2013
	Research and development	$	32,082		$	41,652		$	109,509	$	125,097
	General and administrative		111,650			39,916			401,090		119,886
	Total stock-based compensation expense	$	143,732		$	81,568		$	510,599	$	244,983
Summary of Stock Option Activity	'
	The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2014:
		Options			Weighted-Average
		Outstanding			Exercise
					Price
	Outstanding at December 31, 2013		152,017		$	1.2
	Granted		90,876			8.47
	Exercised		—			—
	Forfeited/cancelled/expired		—			—
	Outstanding and expected to vest at September 30, 2014		242,893			3.92
	Vested and exercisable at September 30, 2014		152,017		$	1.2
Valuation Assumptions Used to Determine Stock-based Expense	'
	Treasury yield for a period consistent with the expected term of the stock award in effect at the time of the grant.
		Nine Months Ended			Nine Months Ended
		September 30,			September 30,
		2014			2013
	Risk-free interest rate		1.4 to 2	%		0.6	%
	Dividend yield		—	%		—	%
	Expected volatility		93 to 100	%		86	%
	Expected life of options, in years		5 and 6.25			6.25
	Weighted-average grant date fair value	$	4.73		$	11.84
Common Stock Reserved for Future Issuance	'
	Common stock reserved for future issuance consists of the following at September 30, 2014:
	Common stock reserved for conversion of preferred stock and warrants		1,916,400
	Common stock options outstanding		242,893
	Authorized for future grant or issuance under the Stock Plan		326,431
	Total		2,485,724

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Shares Excluded From Calculation of Diluted Net Loss Per Share all Potentially Dilutive Stock Options, Preferred Stock and Warrants	'
	The table below presents the potentially dilutive securities that would have been included in the calculation of diluted net loss per share if they were not antidilutive for the periods presented.
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Stock options		123,879		51,178		108,167		49,478
	MabVax Series A preferred stock		—		265,749		183,980		265,749
	MabVax Series B preferred stock		—		203,645		199,489		172,134
	MabVax Series C-1 preferred stock		93,762		—		576,654		—
	Series A-1 preferred stock		1,451,913		—		489,289		—
	Series B preferred stock		158,339		—		81,779		—
	Series C preferred stock		43,644		—		14,708		—
	Total		1,871,537		520,572		1,654,066		487,361

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail)	0 Months Ended	9 Months Ended
	Sep. 08, 2014	Sep. 30, 2014
		Segment
Regulatory Assets [Abstract]	'	'
Reverse stock split on common stock ratio	0.125	'
Reverse stock split, description	'	'8-for-1 Reverse Split
Number of operating segments	'	1

Reverse_Stock_Split_Name_Chang1

Reverse Stock Split, Name Change and Increase in Authorized Shares - Additional Information (Detail)	0 Months Ended
	Sep. 08, 2014	Sep. 30, 2014	Sep. 08, 2014	Dec. 31, 2013
Temporary Equity [Line Items]	'	'	'	'
Common stock, shares authorized	'	150,000,000	150,000,000	'
Preferred stock, shares authorized	'	'	15,000,000	'
Reverse stock split on common stock ratio	0.125	'	'	'
Number of outstanding shares	'	1,868,914	'	230,503
Post Stock Split [Member]	'	'	'	'
Temporary Equity [Line Items]	'	'	'	'
Number of outstanding shares	1,741,617	'	1,741,617	'
Pre Stock Split [Member]	'	'	'	'
Temporary Equity [Line Items]	'	'	'	'
Number of outstanding shares	13,932,937	'	13,932,937	'

Liquidity_and_Going_Concern_Ad

Liquidity and Going Concern - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended				5 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Jul. 07, 2014
							Preferred Stock, Common Stock and Exercise of Warrants [Member]
Change in Accounting Estimate [Line Items]	'	'	'	'	'	'	'
Net loss	($3,282,726)	($1,343,317)	($6,382,336)	($3,166,328)	'	'	'
Net cash used for operating activities	'	'	-5,700,951	-2,325,497	'	'	'
Net cash provided by investing activities	'	'	1,458,539	'	'	'	'
Cash and cash equivalents	3,452,556	95,699	3,452,556	95,699	354,254	421,197	'
Accumulated deficit	-22,877,015	'	-22,877,015	'	-13,972,552	'	'
Financing to be raised through the sale and issuance shares	'	'	'	'	'	'	7,300,000
Issuance costs	'	'	'	'	'	'	$300,000

Merger_with_MabVax_Therapeutic2

Merger with MabVax Therapeutics, Inc - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended
	Jul. 08, 2014	Sep. 30, 2014	Jul. 08, 2014
Loans At Acquisition Date [Line Items]	'	'	'
Merger agreement, entry date	'	12-May-14	'
Merger agreement, effective date	'	8-Jul-14	'
IPR&D Projects [Member]	'	'	'
Loans At Acquisition Date [Line Items]	'	'	'
Research and development costs not yet incurred	'	20,000,000	'
MabVax [Member]	'	'	'
Loans At Acquisition Date [Line Items]	'	'	'
Common stock exchange ratio	'	2.223284	'
Ownership percentage of MabVax equity holders	'	85.00%	'
Ownership percentage of former Telik equity holders	'	15.00%	'
Purchase price consideration	'	'	$6,416,000
Business acquisition, common stock closing price	'	'	$11.20
Business acquisition, common stock shares	572,887	'	'

Merger_with_MabVax_Therapeutic3

Merger with MabVax Therapeutics, Inc - Schedule of Estimated Purchase Price of Acquisition (Detail) (USD $)	Sep. 30, 2014	Jul. 08, 2014
		MabVax [Member]
Loans At Acquisition Date [Line Items]	'	'
Purchase Consideration	'	$6,416,000
Telik Assets	'	-1,710,000
Telik Liabilities	'	1,452,000
Goodwill	$6,157,681	$6,158,000

Convertible_Preferred_Stock_Co2

Convertible Preferred Stock, Common Stock and Warrants - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Jul. 08, 2014

8-May-14

Jul. 07, 2014

Jul. 07, 2014

Sep. 30, 2014

Sep. 03, 2014

Jul. 07, 2014

Sep. 30, 2014

Sep. 30, 2014

Jul. 08, 2014

Jul. 07, 2014

Jul. 07, 2014

Feb. 12, 2014

12-May-14

Feb. 12, 2014

Feb. 12, 2014

Feb. 12, 2014

Jul. 07, 2014

Feb. 12, 2014

Feb. 12, 2014

Feb. 12, 2014

12-May-14

Dec. 31, 2013

8-May-14

Jan. 31, 2014

Dec. 31, 2013

Feb. 28, 2014

Feb. 12, 2014

Feb. 12, 2014

Sep. 30, 2014

Feb. 12, 2014

12-May-14

Sep. 30, 2014

Dec. 31, 2013

Feb. 28, 2014

Dec. 31, 2013

Feb. 28, 2014

Sep. 30, 2014

Sep. 03, 2014

Sep. 03, 2014

Sep. 30, 2014

Series C Preferred Stock Warrants [Member]

Series C Preferred Stock Warrants [Member]

Effective 61 days after providing notice to the Company [Member]

MabVax [Member]

MabVax [Member]

MabVax [Member]

Series B Common Warrants [Member]

Series B Common Warrants [Member]

Maximum [Member]

Maximum [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series B Preferred Stock Purchase Agreement [Member]

Series A Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Series C-1 preferred stock [Member]

Series C-1 preferred stock [Member]

Series C-1 preferred stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series A-1 preferred stock [Member]

Series A preferred stock [Member]

Series A preferred stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series C preferred stock [Member]

Series C preferred stock [Member]

Series C preferred stock [Member]

Series A-1 Preferred Stock [Member]

MabVax [Member]

Private Placement [Member]

Investors in Series C-1 Financing [Member]

Investors in Series C-1 Financing [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

MabVax [Member]

Series C-1 Preferred Stock Purchase Agreement [Member]

Series B Preferred Stock Purchase Agreement [Member]

MabVax [Member]

MabVax [Member]

MabVax [Member]

In the event that less than $3,000,000 were raised from new investors in the Subsequent Capital Raise[Member]

Investors in Series C-1 Financing [Member]

Investors in Series C-1 Financing [Member]

In the event that less than $3,000,000 were raised from new investors in the Subsequent Capital Raise[Member]

Summary Activity In Gold Bullion [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued

'

'

'

'

'

'

'

'

'

326,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,697,702

'

1,168,700

'

'

'

'

'

'

'

'

'

'

2,762,841

Warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,848,851

2,055,000

2,055,260

'

'

'

'

'

'

'

'

'

'

Initial per share exercise price of warrants

'

'

'

'

'

'

'

'

'

'

'

26.64

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.84

3.62

3.62

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of preferred stock and warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,100,000

'

'

'

'

'

'

'

'

$2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued, issuance costs

'

'

'

'

'

'

'

'

'

148,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

126,345

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed dividend related to beneficial conversion feature of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,214,911

'

'

'

'

'

'

'

'

'

'

'

'

'

Financing raised through the sale and issuance of shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

3,000,000

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share price

$6.50

$6.50

'

$11.60

'

'

'

'

'

'

'

'

'

'

$9.14

'

$9.93

$15.08

$15.08

$15.08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock committed to be purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption triggering event, failure to make certain required payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption triggering event, default on indebtedness

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption triggering event, judgments requiring payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.68

'

'

'

'

'

'

'

'

Maximum percentage of shares of common stock issuable upon conversion of preferred stock

4.99%

4.99%

'

'

4.99%

'

'

9.99%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative cash dividends rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

8.00%

8.00%

'

8.00%

'

'

'

'

'

Accretion of redemption value

213,452

307,216

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

307,216

'

'

'

'

'

'

'

'

Liquidation preference

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.68

'

'

'

'

'

'

'

'

Received amount for exchange for warrants

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

'

'

'

'

'

1,827,979

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative preferred stock dividends

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

2,115,000

'

431,000

'

'

'

'

'

Exercise of Series B preferred stock, in shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

194,281

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of Series B preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effect of waived dividend on liquidation preference

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,114,818

'

430,944

'

'

'

'

Preferred stock, redemption price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.17

'

'

$6.82

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate number of preferred stock and warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock and warrants to purchase of shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

78,125

'

'

'

'

'

'

'

'

'

Preferred stock and warrants to purchase of shares of common stock, price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2

'

'

'

'

'

'

'

'

'

Warrants expiry period

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding

'

'

'

'

'

'

'

'

'

'

'

341,301

567,885

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Transfer of securities between Level 1 and Level 2 measurements

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock exchanged for preferred stock

'

'

'

'

'

'

'

'

118,970

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in exchange for common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

118,970

'

Preferred stock converted to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

148,713

'

'

'

Common stock to be issued for each share of convertible preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.25

'

'

Aggregate proceeds from issuance of common stock

'

$2,892,615

'

'

'

'

'

'

'

$2,893,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum percentage of initially issued common stock that may be issued additionally

'

'

'

'

'

'

'

'

'

'

'

'

'

33.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued, par value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

Number of common stock to be issued upon conversion of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,609,000

Options to purchase shares of common stock

'

'

'

'

'

'

'

'

'

'

243,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued pursuant to exercise of merger warrants

'

276,041

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible_Preferred_Stock_Co3

Convertible Preferred Stock, Common Stock and Warrants - Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Financial liabilities	$341,301	'
Warrants [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Financial liabilities	341,301	'
Fair Value, Measurements, Recurring [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Financial assets	25,131	350,557
Financial liabilities	341,301	'
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Financial assets	25,131	350,557
Fair Value, Measurements, Recurring [Member] | Money market funds [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Financial assets	25,131	350,557
Fair Value, Measurements, Recurring [Member] | Money market funds [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Financial assets	25,131	350,557
Fair Value, Measurements, Recurring [Member] | Warrants [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Financial liabilities	$341,301	'

Convertible_Preferred_Stock_Co4

Convertible Preferred Stock, Common Stock and Warrants - Schedule of Changes in the Value of the Warrant Liability (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair value on acquisition	$567,885
Change in fair value	-226,584
Fair value - end of period	$341,301

Convertible_Preferred_Stock_Co5

Convertible Preferred Stock, Common Stock and Warrants - Schedule of Warrant Liability Valuation Assumptions (Detail) (USD $)	0 Months Ended	9 Months Ended
	Jul. 08, 2014	Sep. 30, 2014	Jul. 08, 2014
Fair Value Disclosures [Abstract]	'	'	'
Risk-free interest rate	1.60%	1.70%	'
Dividend yield	'	'	'
Expected volatility	101.60%	87.20%	'
Expected life of options, in years	'4 years 10 months 24 days	'4 years 7 months 10 days	'
Market price for common stock	'	$6.50	$11.60
Warrant exercise price, adjusted	'	$6.21	$26.64
Warrant liability	$567,885	$341,301	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
	Feb. 28, 2014	Sep. 30, 2014	Dec. 31, 2013
Commitment, Contingency And Related Party Transactions [Abstract]	'	'	'
Related party liabilities	$240,000	'	$240,000
Shares of common stock in exchange for cancellation of related party liabilities	44,000	'	'
Severance and benefits costs	748,000	748,000	'
Severance and benefits accrued	'	$239,000	'

Stockbased_Activity_Stockbased

Stock-based Activity - Stock-based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Schedule Of Nonvested Restricted Stock Activity [Line Items]	'	'	'	'
Total stock-based compensation expense	$143,732	$81,568	$510,599	$244,983
Research and Development [Member]	'	'	'	'
Schedule Of Nonvested Restricted Stock Activity [Line Items]	'	'	'	'
Total stock-based compensation expense	32,082	41,652	109,509	125,097
General and administrative [Member]	'	'	'	'
Schedule Of Nonvested Restricted Stock Activity [Line Items]	'	'	'	'
Total stock-based compensation expense	$111,650	$39,916	$401,090	$119,886

Stockbased_Activity_Summary_of

Stock-based Activity - Summary of Activity under Stock Option (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Weighted Average Exercise Price	'	'	'	'
Weighted-Average Exercise Price, Outstanding at beginning of period	'	'	$1.20	'
Weighted-Average Exercise Price, Granted	'	'	$8.47	'
Weighted-Average Exercise Price, Exercised	'	'	'	'
Weighted-Average Exercise Price, Forfeited/cancelled/expired	'	'	'	'
Weighted-Average Exercise Price, Outstanding and expected to vest at end of period	$3.92	'	$3.92	'
Weighted-Average Exercise Price, Vested and exercisable at September 30, 2014	$1.20	'	$1.20	'
Shares Issuable Under Options	'	'	'	'
Options Outstanding, Outstanding at beginning of period	'	'	152,017	'
Options Outstanding, Granted	'	'	90,876	'
Options Outstanding, Exercised	0	0	'	0
Options Outstanding, Forfeited/cancelled/expired	'	'	'	'
Options Outstanding, Outstanding and expected to vest at end of period	242,893	'	242,893	'
Options Outstanding, Vested and exercisable at September 30, 2014	152,017	'	152,017	'

Stockbased_Activity_Additional

Stock-based Activity - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Schedule Of Nonvested Restricted Stock Activity [Line Items]	'	'	'	'
Unrecognized stock-based compensation expense, options	$838,737	'	$838,737	'
Unrecognized stock-based compensation expense, recognition period	'	'	'2 years 8 months 12 days	'
Weighted average remaining Contractual term, stock options outstanding	'	'	'8 years 2 months 12 days	'
Forfeiture rate	'	'	0.00%	'
Stock options granted	'	'	90,876	'
Tax benefits for tax deductions related to stock-based compensation	'	'	$0	'
Stock options exercised	0	0	'	0
Stock options [Member]	'	'	'	'
Schedule Of Nonvested Restricted Stock Activity [Line Items]	'	'	'	'
Stock options vested, number of shares	'	'	0	'
Stock option vesting period	'	'	'4 years	'
Granted Five New Board Members [Member]	'	'	'	'
Schedule Of Nonvested Restricted Stock Activity [Line Items]	'	'	'	'
Stock options granted	'	'	55,580	'

Stockbased_Activity_Valuation_

Stock-based Activity - Valuation Assumptions Used to Determine Stock-based Expense (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	'	0.60%
Dividend yield	'	'
Expected volatility	'	86.00%
Expected life of options, in years	'	'6 years 3 months
Weighted-average grant date fair value	$4.73	$11.84
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	1.40%	'
Expected volatility	93.00%	'
Expected life of options, in years	'5 years	'
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	2.00%	'
Expected volatility	100.00%	'
Expected life of options, in years	'6 years 3 months	'

Stockbased_Activity_Common_Sto

Stock-based Activity - Common Stock Reserved for Future Issuance (Detail)	Sep. 30, 2014
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'
Authorized for future grant or issuance under the Stock Plan	2,485,724
Redeemable Convertible Preferred Stock [Member]	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'
Authorized for future grant or issuance under the Stock Plan	1,916,400
Common stock options outstanding [Member]	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'
Authorized for future grant or issuance under the Stock Plan	242,893
Authorized for future grant or issuance under the Stock Plan [Member]	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'
Authorized for future grant or issuance under the Stock Plan	326,431

Net_Loss_per_Share_Shares_Excl

Net Loss per Share - Shares Excluded From Calculation of Diluted Net Loss Per Share all Potentially Dilutive Stock Options, Preferred Stock and Warrants (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from diluted net loss per common share calculations	1,871,537	520,572	1,654,066	487,361
Stock options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from diluted net loss per common share calculations	123,879	51,178	108,167	49,478
Series B Preferred Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from diluted net loss per common share calculations	158,339	'	81,779	'
Series A-1 preferred stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from diluted net loss per common share calculations	1,451,913	'	489,289	'
Series C preferred stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from diluted net loss per common share calculations	43,644	'	14,708	'
MabVax [Member] | Series A preferred stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from diluted net loss per common share calculations	'	265,749	183,980	265,749
MabVax [Member] | Series B Preferred Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from diluted net loss per common share calculations	'	203,645	199,489	172,134
MabVax [Member] | Series C-1 preferred stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from diluted net loss per common share calculations	93,762	'	576,654	'

Contracts_And_Agreements_Addit

Contracts And Agreements - Additional Information (Detail) (Phase 2 [Member], NCI PET imaging agent [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Aug. 25, 2014
Phase 2 [Member] | NCI PET imaging agent [Member]	'
Agreements [Line Items]	'
Contract awarded	$1.50

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
	Feb. 28, 2014	Sep. 30, 2014
		Employees
Operating Leased Assets [Line Items]	'	'
Number of employees separated	'	9
Severance and benefits costs	$748,000	$748,000
Severance and benefits costs to be paid	'	239,000
Porter Drive Facility [Member]	'	'
Operating Leased Assets [Line Items]	'	'
Contingent lease termination fee	'	590,504
Additional financing amount	'	$15,000,000

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail)	9 Months Ended		0 Months Ended
	Sep. 30, 2014	Oct. 03, 2014	Oct. 14, 2014	Oct. 03, 2014
		Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
			Common Stock [Member]	Common Stock [Member]
Subsequent Event [Line Items]	'	'	'	'
Common stock issued pursuant to exercise of merger warrants	276,041	'	'	314,118
Number of warrants delivered	'	504,264	'	'
Common stock shares issued for registration	'	'	1,615,070	'